Pompe Gene Therapy- Screening for Eligibility
Completed
Conditions studied: Pompe Disease (Late-onset)
In brief
The purpose of this study is to determine eligibility for the future clinical trial of gene therapy in adults with late-onset Pompe disease. This screening protocol will enroll up to 20 adults patients (\>=18 yo) with late-onset Pompe disease. Study assessments include review of medical history, vital signs, physical examination, muscle function testing, lung function testing, blood and urine collection, serum pregnancy test and ECG. The study results will be collected to perform descriptive statistical analysis and used to determine eligibility for the proposed clinical trial of gene therapy in the future.
Key facts
- Study ID
- NCT03285126
- Run by
- Duke University
- People needed
- 19
- Starts
- 2017-11-01
- Expected to finish
- 2019-06-29
- Last updated by the study team
- 2019-07-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of Pompe disease by blood or skin fibroblast GAA assay and two pathogenic variants in the GAA gene.
- Age: at least 18 years at enrollment.
- Subjects are capable of giving written consent.
- Receiving ERT at a stable dose for at least 104 weeks.
You may not qualify if…
- Any condition that would interfere with participation in the study as determined by the principal investigator.
- Pregnancy or nursing mothers.
- History of active hepatitis B, hepatitis C, or cirrhosis
- Receiving any investigational agent.
Where it is running
- Duke University Medical Center — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.